Ocrevus

(Ocrelizumab)

ApprovedMonoclonal antibody

Ocrelizumab is used to treat multiple sclerosis, a disease where the immune system attacks the brain and spinal cord, causing weakness and disability. It works by reducing certain immune cells that damage the nervous system.[2] Ocrevus is currently approved and in use across 16 indications[4].[1]

Ocrevus is one of 320 monoclonal antibody programs targeting Systemic Lupus Erythematosus. It is currently in Approved.

Indications

Total Trials

Active Trials

319

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Non-Hodgkins LymphomaActive, not recruiting

AutoimmunityActive, not recruiting

LymphomaActive, not recruiting

Chronic Progressive Multiple SclerosisUnknown

Relapsing-Remitting Multiple SclerosisUnknown

PsychosisActive, not recruiting

Primary Progressive Multiple SclerosisActive, not recruiting

Autoimmune EncephalitisActive, not recruiting

Diffuse Large B-Cell LymphomaUnknown

Systemic Lupus ErythematosusPhase 3

Active, not recruiting

Non-Hodgkins LymphomaPhase 1

Active, not recruiting

AutoimmunityPhase 1/Phase 2

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Chronic Progressive Multiple SclerosisPreclinical

Unknown

Relapsing-Remitting Multiple SclerosisPreclinical

Unknown

PsychosisPhase 1

Active, not recruiting

Primary Progressive Multiple SclerosisPhase 3

Active, not recruiting

Autoimmune EncephalitisPhase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPreclinical

Unknown

Showing 10 of 16 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Ocrevus

Roche

Approved

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Tafasitamab

Incyte

Preclinical

7 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Multiple Sclerosis

NCT03523858

Q3 2027

Post-ApprovalActive, not recruiting

Multiple Sclerosis

NCT04466150

Phase 3Active, not recruiting

Multiple Sclerosis, Primary Progressive

NCT04544449

Phase 3Active, not recruiting

Primary Progressive Multiple Sclerosis

NCT04548999

Q4 2027

Phase 3Recruiting

MPA

NCT06700343

Phase 3Active, not recruiting

Multiple Sclerosis

NCT05269004

Clinical

Trials by Indication[1]

Multiple Sclerosis37 trials

Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM

Unknown status·HHospital Italiano de Buenos Aires··NCT03784547·100 enrolled

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Completed· Roche logo

Roche·Phase 3·NCT05232825·236 enrolled

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

Recruiting· Roche logo

Roche··NCT06780150·842 enrolled

Show 34 more trials

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04544436·864 enrolled

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Active, not recruiting·UUniversity of California, San Francisco·Phase 4·NCT04466150·30 enrolled

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Completed· Roche logo

Roche·Phase 3·NCT02861014·681 enrolled

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

Recruiting·AAmsterdam UMC, location VUmc·Phase 4·NCT05296161·296 enrolled

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

Terminated·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2·NCT04971005·1 enrolled

A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

Withdrawn· Roche logo

Roche·Phase 4·NCT05208840

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Terminated· Roche logo

Roche·Phase 3·NCT03085810·1,225 enrolled

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Completed· Roche logo

Roche·Phase 3·NCT01247324·821 enrolled

A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting

Completed· Roche logo

Roche·Phase 4·NCT03589105·423 enrolled

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Suspended·IIndapta Therapeutics, INC.·Phase 1·NCT06677710·34 enrolled

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05269004·1,300 enrolled

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Completed·UUniversity of Chicago··NCT03344094·30 enrolled

Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

Completed·UUniversity of South Florida··NCT03562975·18 enrolled

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Recruiting· Roche logo

Roche·Phase 3·NCT06675955·500 enrolled

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03523858·927 enrolled

Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis

Completed·UUniversity at Buffalo··NCT03025269·30 enrolled

Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

Completed·CCinnagen·Phase 3·NCT04966338·170 enrolled

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Recruiting·NNorthwestern University··NCT07207148·100 enrolled

Effects of Ocrevus in Relapsing Multiple Sclerosis

Active, not recruiting·GGeorgia State University·Phase 4·NCT04387734·60 enrolled

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Completed· Roche logo

Roche·Phase 3·NCT01412333·835 enrolled

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Active, not recruiting·RRigshospitalet, Denmark·Phase 3·NCT04688788·600 enrolled

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

Recruiting·UUniversity of California, San Francisco·Phase 4·NCT06495593·5 enrolled

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

Completed· Novartis logo

Novartis··NCT04676555·2 enrolled

Short-term B-cell Depletion in Relapsing Multiple Sclerosis

Completed·JJohns Hopkins University·Phase 4·NCT03853746·10 enrolled

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

Completed·NNYU Langone Health··NCT04855617·122 enrolled

This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Completed· Roche logo

Roche·Phase 3·NCT03599245·1,055 enrolled

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

Completed· Roche logo

Roche·Phase 4·NCT04377555·179 enrolled

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

Completed· Roche logo

Roche·Phase 1·NCT03972306·134 enrolled

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Completed· Roche logo

Roche·Phase 3·NCT02637856·608 enrolled

Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

Not yet recruiting·JJohns Hopkins University·Phase 4·NCT07389590·50 enrolled

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

Completed·JJohns Hopkins University·Phase 4·NCT04261790·10 enrolled

Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.

Terminated·YYale University·Phase 4·NCT04877457·3 enrolled

A Phase II, Randomized, Open-label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients With Multiple Sclerosis

Recruiting· Roche logo

Roche·Phase 2·NCT07074886·182 enrolled

Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS05)

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Approved·NCT05285891·123 enrolled

Rheumatoid Arthritis8 trials

A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)

Terminated· Roche logo

Roche·Phase 3·NCT00485589·613 enrolled

A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Terminated· Roche logo

Roche·Phase 1/2·NCT02720120·175 enrolled

A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 1/2·NCT00077870·237 enrolled

Show 5 more trials

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

Terminated· Roche logo

Roche·Phase 2·NCT00808210·28 enrolled

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Terminated· Roche logo

Roche·Phase 3·NCT00476996·836 enrolled

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis

Terminated· Roche logo

Roche·Phase 2·NCT00779220·152 enrolled

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

Terminated· Roche logo

Roche·Phase 3·NCT00406419·1,015 enrolled

A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

Terminated· Roche logo

Roche·Phase 3·NCT00673920·314 enrolled

Primary Progressive Multiple Sclerosis7 trials

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

Completed· Roche logo

Roche··NCT03593590·1,710 enrolled

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Completed· Roche logo

Roche·Phase 3·NCT01194570·735 enrolled

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

Completed· Roche logo

Roche·Phase 3·NCT03606460·141 enrolled

Show 4 more trials

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

No longer available· Roche logo

Roche··NCT02807285

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04035005·1,013 enrolled

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

Completed· Roche logo

Roche·Phase 3·NCT02688985·131 enrolled

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04548999·769 enrolled

Relapsing-Remitting Multiple Sclerosis4 trials

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Recruiting·BBiocad·Phase 3·NCT07321093·292 enrolled

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05123703·188 enrolled

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Active, not recruiting· Roche logo

Roche·Phase 2·NCT04075266·23 enrolled

Show 1 more trial

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Completed· Roche logo

Roche·Phase 2·NCT00676715·220 enrolled

ESS2 trials

Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in MS

Active, not recruiting·DDr Recai Turkoglu··NCT04874597·30 enrolled

Ocrelizumab Access by Socio-Economic Status

Completed·—··NCT05131984·800 enrolled

19 more indications

Pregnancy2 trials

A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

Completed· Roche logo

Roche·Phase 4·NCT04998812·70 enrolled

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Recruiting· Biogen logo

Biogen··NCT05688436·1,178 enrolled

Systemic Lupus Erythematosus2 trials

A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)

Terminated· Roche logo

Roche·Phase 3·NCT00626197·381 enrolled

A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)

Terminated· Roche logo

Roche·Phase 3·NCT00539838·33 enrolled

Relapsing Multiple Sclerosis2 trials

A Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Chinese Patients With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Active, not recruiting· Roche logo

Roche·Approved·NCT07483450·60 enrolled

A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib

Recruiting· Novartis logo

Novartis·Phase 3·NCT06846281·360 enrolled

Infusion1 trial

Home Based Infusions for Ocrelizumab

Recruiting·UUniversity of Colorado, Denver·Phase 4·NCT04650321·110 enrolled

Immune1 trial

Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03691077·51 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy

Unknown status·CClaudio Gobbi··NCT04640818·45 enrolled

Autoimmunity1 trial

Ocrelizumab for Psychosis by Autoimmunity

Unknown status·TThe Methodist Hospital Research Institute·Phase 1/2·NCT03971487·40 enrolled

MPA1 trial

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Recruiting· Amgen logo

Amgen·Phase 3·NCT06700343·444 enrolled

Autoimmune Encephalitis1 trial

Efficacy of Ocrelizumab in Autoimmune Encephalitis

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT03835728·3 enrolled

Lymphoma1 trial

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Completed· Roche logo

Roche·Phase 1/2·NCT02723071·48 enrolled

Autologous Hematopoietic Stem Cell Transplantation1 trial

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

Active, not recruiting·HHaukeland University Hospital·Phase 3·NCT03477500·100 enrolled

Infants1 trial

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

Completed· Roche logo

Roche·Phase 4·NCT04998851·26 enrolled

Breast1 trial

Ocrelizumab in Breastmilk

Completed·UUniversity of California, San Francisco··NCT04387110·30 enrolled

Randomized1 trial

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

Recruiting·FFondation Ophtalmologique Adolphe de Rothschild·Phase 3·NCT05999604·244 enrolled

Effectiveness1 trial

LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB

Active, not recruiting·—·Phase 3·NCT05210621·72 enrolled

Itching1 trial

Safety of Switching From Rituximab to Ocrelizumab in MS Patients

Completed·UUniversity of Colorado, Denver·Phase 3·NCT02980042·200 enrolled

Progressive Multiple Sclerosis1 trial

A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis

Recruiting· Roche logo

Roche·Phase 2·NCT07282574·360 enrolled

Multiple Sclerosis, Primary Progressive1 trial

A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis.

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04544449·985 enrolled

Unspecified4 trials

Ocrelizumab Effects on the Metabolome in MS

Completed·JJohns Hopkins University··NCT03873389·25 enrolled

WOE of Anti-CD20 Therapies

Completed· Novartis logo

Novartis··NCT06121349·157 enrolled

Mechanistic Study of Ocrevus

Completed·UUniversity of Michigan··NCT04459988·35 enrolled

Show 1 more trial

Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Active, not recruiting·HHaukeland University Hospital·Phase 3·NCT04578639·214 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 28, 2017

OCREVUS

BLA BLA761053

Sources

References

[1]
ClinicalTrials.gov — 83 trial records for Ocrelizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Ocrevus drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ocrelizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ocrelizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761053). U.S. Food & Drug Administration.
[6]
PubMed — 2 publications indexed for Ocrelizumab. U.S. National Library of Medicine.
[7]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CD20 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche

Key Publications[6]

Ocrelizumab in Primary Progressive Multiple Sclerosis: Extended Follow-Up

Lancet NeurolSep 15, 2022DOI: 10.1016/S1474-4422(22)00326-1

Early Versus Delayed Ocrelizumab in Relapsing Multiple Sclerosis

N Engl J MedMay 22, 2022DOI: 10.1056/NEJMoa2202412

Ocrevus

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Trials by Indication[1]

Multiple Sclerosis37 trials

Rheumatoid Arthritis8 trials

Primary Progressive Multiple Sclerosis7 trials

Relapsing-Remitting Multiple Sclerosis4 trials

ESS2 trials

Pregnancy2 trials

Systemic Lupus Erythematosus2 trials

Relapsing Multiple Sclerosis2 trials

Infusion1 trial

Immune1 trial

Safety and Efficacy1 trial

Autoimmunity1 trial

MPA1 trial

Autoimmune Encephalitis1 trial

Lymphoma1 trial

Autologous Hematopoietic Stem Cell Transplantation1 trial

Infants1 trial

Breast1 trial

Randomized1 trial

Effectiveness1 trial

Itching1 trial

Progressive Multiple Sclerosis1 trial

Multiple Sclerosis, Primary Progressive1 trial

Unspecified4 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Key Publications[6]

Related News